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Abstract: Key pathological features of cerebral small vessel disease (cSVD) include impairment of the
blood brain barrier (BBB) and the progression of white matter lesions (WMLs) amongst other structural
lesions, leading to the clinical manifestations of cSVD. The function of endothelial cells (ECs) is of
major importance to maintain a proper BBB. ECs interact with several cell types to provide structural
and functional support to the brain. Oligodendrocytes (OLs) myelinate axons in the central nervous
system and are crucial in sustaining the integrity of white matter. The interplay between ECs and OLs
and their precursor cells (OPCs) has received limited attention yet seems of relevance for the study of
BBB dysfunction and white matter injury in cSVD. Emerging evidence shows a crosstalk between ECs
and OPCs/OLs, mediated by signaling through the Wingless and Int-1 (WNT)/β-catenin pathway.
As the latter is involved in EC function (e.g., angiogenesis) and oligodendrogenesis, we reviewed the
role of WNT/β-catenin signaling for both cell types and performed a systematic search to identify
studies describing a WNT-mediated interplay between ECs and OPCs/OLs. Dysregulation of this
interaction may limit remyelination of WMLs and render the BBB leaky, thereby initiating a vicious
neuroinflammatory cycle. A better understanding of the role of this signaling pathway in EC–OL
crosstalk is essential in understanding cSVD development.
Keywords: cerebral small vessel disease; WNT; β-catenin; oligodendrocytes; oligodendrocyte
precursor cells; endothelial cells
1. Introduction
Cerebral small vessel disease (cSVD) is an umbrella term used to describe different pathological
processes that affect the small vessels of the brain, including small arteries, arterioles, capillaries, and
small veins, and is associated with brain structural lesions and eventual cognitive impairment [1].
With cSVD accounting for up to 25% of all stroke and 45% of dementia, it is seen as a common cause of
cognitive impairment worldwide [2]. Beyond cognitive impairment, mood and gait disorders are also
often seen in cSVD patients [3]. Although recent advances have led to an improved diagnosis and
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understanding of cSVD, its exact pathogenesis is still unknown. However, damage to the blood brain
barrier (BBB) is recognized as an early pathological step in cSVD, often resulting from the exposure to
cardiovascular risk factors, such as hypertension and diabetes [2,4,5].
BBB dysfunction has been evidenced in experimental animal models of cSVD as well as in cSVD
patients [6–8]. Endothelial cells (ECs) are essential for BBB function due to their tight junction (TJ)
proteins that prevent the passive entrance of cells and macromolecules into the brain. Endothelial
dysfunction is therefore a key contributor to BBB dysfunction and is present in several brain
pathologies, including stroke, multiple sclerosis (MS), and Alzheimer’s disease [9]. In addition
to the endothelial barrier, BBB integrity also relies on non-neuronal cells, such as pericytes, astrocytes,
and oligodendrocytes (OLs) [10]. Although studies are scarce, the involvement of different cell types,
especially OLs, might play a critical role in the pathophysiology of cSVD. Both OLs and oligodendrocyte
precursor cells (OPCs) are able to lower the brain endothelial permeability when co-cultured with
primary brain ECs [11]. In addition, OL dysfunction can cause white matter loss and BBB disruption,
two important features seen in cSVD patients [10,12,13]. A common factor that may facilitate an
interaction between ECs and OPCs/OLs is platelet-derived growth factor (PDGF) as ECs and OPCs
secrete PDGF and express its receptor (PDGFRα). The tightening of the BBB by OLs seems, however,
not to depend on the PDGF/PDGFRα signaling, as it cannot be prevented by a PDGFRα antagonist [11].
This suggests that other pathways might play a critical role in the interaction between ECs and
OPCs/OLs. The Wingless and Int-1 (WNT)/β-catenin pathway, largely described for its function within
ECs and OPCs/OLs may be crucial in this crosstalk [14,15].
Although both ECs and OLs (and their precursor cells) are involved in BBB integrity, studies
examining these cells and their interaction in the context of cSVD are limited. This review aimed to
summarize the published findings on the crosstalk between ECs and OPCs/OLs, and in particular the
role played by WNT/β-catenin signaling in this interaction. First, we briefly address the respective
roles of WNTs in ECs and OPCs/OLs. Second, we discuss the current knowledge on EC–OL interaction.
Third, we present studies found via a systematic search that have identified a role for WNT signaling
in this crosstalk. Finally, we discuss the potential implications of these findings for cSVD pathology
before we formulate a conclusion.
2. Pathology of Cerebral Small Vessel Disease
cSVD is a heterogeneous disease that includes genetic and sporadic forms. Sporadic cSVD,
the most prevalent form of cSVD, can be further subdivided into amyloidal and non-amyloidal
subtypes [1,10,16]. Sporadic cSVD is associated with age and the presence of cardiovascular risk factors.
Hypertension is considered as the major modifiable risk factor for the development of cSVD and
vascular cognitive impairment [16,17]. The thickening, stiffening, and narrowing of extra-cranial and
cranial vessels induced by hypertension can lead to brain hypoperfusion, with subsequent hypoxia,
BBB impairment, neuroinflammation, and the appearance of white matter lesions (WMLs), ultimately
leading to demyelination and neurodegeneration [18–21]. The pathological cascade induced by
hypertension has been summarized by the ‘three hit’ hypothesis [22]. The initial hit is hypertension
itself, which can initiate an ischemic insult leading to local tissue hypoxia. The local hypoxic state,
which is considered as the second hit, can promote damage and inflammation, which represents the
third and final hit. In the course of this pathological cascade, hypoxia can increase BBB permeability
and induce myelin breakdown either directly and/or indirectly via the expression of cytokines, such
as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, secreted by microglia and macrophages.
Reactive microglia and brain macrophages can alter the BBB integrity itself and also damage the
white matter tissue and its supporting cells, such as OLs, leading to myelin breakdown and vasogenic
cerebral edema [22]. Altogether, neuroinflammation and myelin breakdown can cause WMLs and the
development of cognitive impairment [22,23].
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Taken together, our current knowledge on cSVD pathology indicates a role for ECs and OLs in
maintaining the integrity of the white matter and the BBB, and suggests that their dysfunction could
be critical in the course of cSVD development.
3. Brain Endothelial Cells
Brain ECs harbor specific features compared to peripheral ECs, namely the presence of TJ
proteins. This is a key feature in maintaining the central nervous system (CNS) microenvironment
and to protect the brain from invading pathogens, immune cells, toxic compounds, or alternating
ionic concentrations that can affect normal cerebral function [24]. Pericyte and astrocyte end-feet
support this barrier by surrounding the EC [25,26]. TJ link adjacent ECs together by forming
homodimer transmembrane proteins, which are important in maintaining the tightly regulated brain
microenvironment. Dysfunction of these proteins can cause leakage of the BBB and disruption of brain
functions [27]. The brain requires certain nutrients to maintain its normal function, thus controlled
permeability is required for normal brain function. The EC in the BBB are specialized in allowing the
transport of certain molecules and cells when needed, such as glucose for energy or immune cells
during inflammation [28,29].
ECs also play a key role in regulating local cerebral blood flow in response to neuronal activity
and their underlying metabolic needs. This is regulated by the relaxation of smooth muscle cells
and pericytes surrounding the larger vessels and capillaries, respectively, mediated by the release of
nitric oxide (NO), synthesized by the endothelial NO synthase (eNOS). Upon eNOS deactivation, or
impaired vasodilation, the cerebrovascular tone is increased, potentially leading to hypoxia in the
corresponding areas [24]. This highlights the importance of tight regulation of the vascular diameter
by ECs and the adverse consequences of malfunctioning of this system.
Microvascular dysfunction has been proposed as an early sign of cSVD, preceding the occurrence
of structural lesions, such as WMLs. Endothelial dysfunction causes BBB leakage and inflammation,
which has been suggested to cause lacunar strokes, white matter hyperintensities, and cerebral
microbleeds seen in cSVD [2,24,27,30]. An increased plasma concentration of markers of endothelial
activation, such as vascular cell adhesion molecule (VCAM)-1 and intracellular adhesion molecule
(ICAM)-1, has been observed in patients with cSVD compared to control subjects [30]. Furthermore,
beyond their own dysfunction, the release of detrimental mediators by diseased ECs may also affect
other brain cells, further aggravating cSVD progression [24].
4. Oligodendrocytes
OLs are the cells responsible for the production of myelin, the isolating fatty sheath surrounding
axons that provides structural protection, and facilitate fast electrical signal transduction along CNS
axons. In addition to this role in action potential conduction, recent work has revealed additional
roles in various processes, including trophic and metabolic support of neurons [31–35], information
processing in neural circuits [36], and interactions with other CNS cell types, such as ECs [37,38].
Myelinating OLs are generated through a sequence of developmental steps involving four
stages: OPCs, late OPCs, immature OLs, and mature myelinating OLs [39]. During this
developmental sequence, OPCs migrate to sites requiring myelination, where they proliferate and
undergo a morphological differentiation that marks their transition into late OPCs (also known as
preoligodendrocytes). Late OPCs exhibit highly branched process arbors whose terminal branches
make contact with numerous neuronal compartments, including axons [40,41]. This developmental
sequence continues as late OPCs exit the cell cycle and differentiate into immature OLs that upregulate
the expression of myelin genes and convert some of their initial axonal contacts into loose membrane
wraps. As OL maturation progresses, these early ensheathments are elongated and compacted to
form mature myelin sheaths. Other non-myelinating process branches are resorbed so that in the final
mature OL, all process branches support myelinating segments. Of note, a significant number of OPCs
persist in CNS tissues beyond the period of developmental myelination, where they provide a pool of
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precursors that can be recruited in the case of injury [42–44]. The rate of OPC differentiation decreases
in the adult CNS [43], and while some OPCs differentiate to produce myelinating OLs, the majority
remain as OPCs and are not involved in myelin sheath production [42]. Yeung et al. suggest that human
OLs have the ability to remodel the myelin sheaths without the need for the generation of OLs from
OPCs [45]. However, other studies show that there is a gradual production of newly differentiated OLs
that engage in de novo myelination and myelin remodeling in the adult CNS [46,47]. Factors released
by OPCs and OLs, such as insulin-like growth factor 1 (IGF-1) and brain-derived neurotrophic factor
(BDNF), induce neuronal cell survival [31,48], indicating that OLs indeed provide important trophic
support for axonal maintenance and survival. Hypertension, hypoxia, and inflammation might disrupt
these factors, leading to OL cell death and damage to the integrity of white matter tissues. Loss of
white matter due to hypoperfusion-induced OL death and myelin loss in cSVD has been demonstrated
in experimental animal models [49–51]. Cognitive impairment associated with the loss of OLs has been
observed, for instance, following brain hypoperfusion in rats via the permanent bilateral occlusion
of the common carotid arteries [49]. Hypoperfusion led to an initial increase in OPCs, which was
followed by an increase in OPC cell death that produced a net decrease in the number of mature
OLs in this chronic hypoperfusion rat model [50]. A similar finding was observed in spontaneously
hypertensive rat-stroke prone (SHRSP) subjected to brain hypoperfusion in association with increased
inflammatory mediators [51]. Overall, the complex multi-step process involved in OL development
and function, and its dependence on tightly controlled regulatory mechanisms, renders OLs highly
sensitive to pathological conditions in both the developing and mature CNS.
Consequently, the emergence of a local or global brain hypoperfusion can affect both OPC/OL
function and the factors secreted by these cells under these conditions. One group of these secreted
factors are the WNT proteins and their signaling molecules, an upregulation of which was found
after exposure of OPCs to hypoxic conditions, suggesting that they may play major roles in brain
hypoxia [52]. In fact, these proteins play a complex role in both white matter integrity and angiogenesis,
with a key role in both OPC fate, OL survival, and EC proliferation [14,15,52]. Taken together, these
findings suggest that WNT signaling may be a key regulator of OPC–OL interaction, and an important
mediator in cSVD pathology.
5. WNT Signaling in Endothelial Cells and Oligodendrocytes
5.1. WNT Signaling
WNT signaling is typically categorized into two pathways: The β-catenin- and non-β-catenin-
mediated pathways, with the latter being further sub-categorized. The non-beta-catenin-mediated
pathways involve all WNT pathways that do not lead to the stabilization of β-catenin and plays a
role in processes including cell polarization, cell fate, inflammatory response, and cell migration [53].
The β-catenin-mediated WNT signaling pathway leads to the intracellular stabilization of β-catenin,
resulting in its translocation to the nucleus and the transcription of numerous genes involved in cell
proliferation, differentiation, tissue expansion, cell fate, and many more [54]. In the absence of WNT
proteins, β-catenin is phosphorylated by a protein complex formed by glycogen synthase kinase 3β
(GSK-3β), Axin, adenomatous polyposis coli (APC), and casein kinase-1 (CK-1). Phosphorylation of
β-catenin by this so-called destruction complex leads to its degradation by the ubiquitin proteasome.
Secreted WNT proteins require two distinct receptor families for their intracellular signaling, namely
the Frizzled (Fzd) and the low-density lipoprotein (LDL) receptor-related protein 5 or 6 (LRP5/6).
Binding of WNT to Fzd and its co-receptor LRP5/6 results in the recruitment of the disheveled (Dsh)
protein to the plasma membrane. This leads to the recruitment of several components of the β-catenin
phosphorylation complex and their inhibition, which in turn leads to the accumulation of β-catenin
in the cytoplasm. Increased cytoplasmic β-catenin promotes its translocation to the nucleus and its
binding to transcription factors, leading to transcription of its target genes (Figure 1) [14]. An extensive
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description of these different WNT signaling pathways is beyond the scope of this review but can be
found in a recent publication from our group [14].
Figure 1. Schematic representation of the Wingless and Int-1 (WNT)/β-catenin signaling pathway. In the
non-active state (left panel), β-catenin is phosphorylated by a multi-component complex containing
glycogen synthase kinase 3β (GSK-3β), Axin, adenomatous polyposis coli (APC), and casein kinase-1
(CK-1). This causes β-catenin to be phosphorylated for degradation by the proteasome complex. In
the active state (right panel), a WNT ligand binds to its receptor and co-receptor, Frizzled (Fzd), and
low density lipoprotein (LDL) receptor-related protein 5 or 6 (LRP5/6), respectively, and causes the
recruitment of components of the β-catenin phosphorylating complex to the membrane together with
disheveled (DSH). This leads to the cytoplasmic accumulation of β-catenin and its translocation to
the nucleus, eventually binding members of the T-cell factor/lymphoid enhancing factor (TCF/LEF)
transcription factors and activating transcription of target genes.
5.2. WNT Signaling in Brain Endothelial Cells
β-catenin is essential for the formation and maintenance of vascular integrity and controls BBB TJ
formation [55,56]. The first steps of blood vessel formation seem to rely on WNT/β-catenin signaling
promoting EC-specific differentiation of pluripotent stem cells, an essential step in vasculogenesis
(the initial blood vessel formation) [14]. WNT/β-catenin also induces the expression of TJ and glucose
transporter 1 (Glut1) proteins, which are key features of brain ECs. Besides differentiation, several
WNTs have also been reported to induce EC proliferation and migration to promote vessel assembly [57].
WNT signaling is also essential for the formation of new blood vessels from pre-existing ones, called
angiogenesis [14]. In a non-angiogenic state, cytoplasmic β-catenin is constantly degraded and thus
does not result in the formation of new vasculature. When WNT signaling is activated, stabilization of
β-catenin leads to angiogenesis. Angiogenesis is further regulated by the negative feedback mechanism
involving the activation of c-Casitas B-lineage lymphoma (c-Cbl). Phosphorylated c-Cbl promotes the
degradation of active β-catenin, and thus functions as a negative regulator of angiogenesis [58]. CNS
angiogenesis has been shown to be dependent dominantly on the β-catenin-mediated WNT signaling
ligands WNT7a and WNT7b [59]. These ligands are dependent on coactivators G protein-coupled
receptor 124 (GPR124) and Reck expressed by the EC, which enhance WNT7a/7b signaling pathways [60].
Benz et al. showed that brain areas lacking a BBB have ECs with low levels of β-catenin activation
due to the absence of WNT receptors. Increased β-catenin activation resulted in increased endothelial
expression of the TJ protein claudin5, and was associated with a reduction of BBB permeability in the
corresponding areas [61]. In addition to angiogenesis, the expression of TJ proteins, such as claudin3
and claudin5, which maintain BBB integrity, is also regulated by WNT/β-catenin signaling [56,61].
In vitro stabilization of β-catenin with WNT3a treatment in primary ECs resulted in an increased
expression of claudin3, and the formation of TJ and BBB characteristics [56], while in vivo overactivation
of β-catenin in transgenic mice led to an increased expression of claudin5 [61].
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Taken together, this demonstrates the essential role of WNT/β-catenin signaling in the formation
and integrity of the BBB. Interestingly, WNT7a and WNT7b, which drive angiogenesis, are the
predominant WNT proteins expressed by OPCs [52,62].
5.3. WNT Signaling in Oligodendrocytes
WNT/β-catenin signaling was initially suggested to exert an inhibitory effect on oligodendrogenesis
and differentiation, although it is now clear that this pathway regulates multiple events during the
OPC developmental stages [15,63,64]. While some studies have identified a WNT/β-catenin-mediated
repressive function for the OPC specification from neuronal stem cells (NSCs) during prenatal
development [63,65], other studies showed that WNT signaling was dispensable or could even enhance
OPC differentiation [66,67]. It has become clear that WNT signaling plays a complex role in the fate of
OPCs in a context-dependent manner, depending on the developmental stage, location in the CNS,
cell type, exposure level, and possible interactions with other pathways affecting the cell fate [15,64].
Guo et al. proposed a working model on the multimodal role of WNT/β-catenin signaling in OPC
development [15]. Low levels of β-catenin signaling promote OPC differentiation to immature OLs
during development, whereas high levels inhibit OPC density and differentiation. Similar findings were
observed during OL maturation, where the exact role of WNT/β-catenin signaling on OL maturation
remains unclear [15]. Olig2Cre; Da-Cat mice, which have dominant-active β-catenin in OPCs and OLs,
had decreased numbers of myelin proteolipid protein (PLP) expressing OLs, which was associated with
hypomyelination, while OPC numbers were not affected [66]. On the contrary, Tawk et al. reported
that WNT/β-catenin signaling plays a role in activating this myelin gene in OLs. They showed that
inhibition of WNT signaling components by small interfering RNA (siRNA) resulted in a decrease
in plp expression levels, while a three-fold increase in the expression of this myelin gene protein was
observed following WNT/β-catenin activation by WNT1 [67]. Myelin is a major component within
white matter, and damage to myelin proteins is widely seen in cSVD as discussed previously. It is
therefore important to clarify the effects of WNT signaling on OPC differentiation and maturation in
the context of demyelination and remyelination.
After demyelination, activation of WNT/β-catenin seems to inhibit OPC differentiation and to
decrease myelin density. Fancy et al. reported a decrease in PLP-expressing OLs, 14 days after a
lysolecithin (LPC)-induced lesion in Olig2Cre;Da-Cat mice. They also found a decrease in remyelination
after LPC-induced demyelination in mice lacking one Apc allele or containing a complete deletion of
the Axin2 gene, which both caused an increase in β-catenin levels [66]. In line with this finding, the
inhibition of WNT/β-catenin by aspirin was associated with increased OL differentiation [68]. However,
in another study, neither Apc single-allele conditional knockout nor one-allele nonsense truncated
mutation differed in the levels of WNT/β-catenin signal when compared to wild type (WT) mice [69].
This suggests that the previous reported delay in OPC differentiation might have resulted from
β-catenin-independent effects of Apc deletion. On the contrary, an increase in the WNT transcription
mediator gene, transcription factor-4 (TCF4 (also known as TCF7L2)), was reported following white
matter demyelination in rodents and in active areas of MS lesions, indicating a beneficial role for WNT
signaling in remyelination [66]. It was, however, demonstrated that TCF4 was expressed only early in
remyelination in both mice and MS patients, and not in later stages or in chronic lesions [70,71]. This
might indicate an early OPC recruitment via WNT/β-catenin signaling, which has been reported to
play a role in OPC migration and the attachment to vessels [72], as a rescue mechanism in response
to demyelination.
Although sometimes contradictory at first sight, these results highlight a crucial role for
WNT/β-catenin in OL function that may largely depend on the timing, context, and cellular
environment. Taken together, activation of WNT/β-catenin signaling in demyelination appears
to inhibit OL development and decreases myelin production, resulting in a remyelination failure that
could contribute to the development of the WML seen in cSVD.
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6. Oligodendrocyte–Endothelial Cell Crosstalk
Although both ECs and OPCs/OLs are of importance for the BBB integrity, the interaction
between ECs and OPCs/OLs and their role in cSVD remain largely unclear. It has been suggested
that EC dysfunction might alter OL function, and vice versa [10]. There is no direct evidence linking
EC–OL interaction and cSVD. However, early investigations on the SHRSP, a hypertensive rat model
that recapitulates many brain structural abnormalities characteristic of cSVD pathology, including
WMLs, suggest that endothelial dysfunction precedes and leads to alterations in myelin and white
matter [73–75]. A reciprocal interaction between ECs and OLs was also demonstrated in an animal
model of neurofibromatosis. OL-specific overactivation of Ras signaling in these animals led to an
aberrant production of NO in addition to dysregulation of TJ proteins in both ECs and myelin sheaths.
Ras overexpression also led to enlarged perivascular spaces and BBB leakages, which correlated with
myelin breakdown. This indicates that OL-specific changes might have an effect on ECs and lead to
features of cSVD pathology [76]. In addition, mice with endothelial dysfunction presented increased
remnants of capillaries in the form of string vessels and decreased numbers of OPCs in the white
matter [77]. These abnormalities predate other cSVD pathology in both animal models and human
post-mortem tissue, suggesting an interplay between the endothelium and myelinating cells [77,78].
Aria and Lo were the first to describe a clear interaction between ECs and OLs in an in vitro
model by culturing rat OPCs in human brain EC-conditioned medium, which induced an increased
OPC proliferation rate. They suggested that EC-secreted factors, such as fibroblast growth factor (FGF)
and BDNF, mediated these effects [79]. In turn, OPCs seem to affect ECs in culture as well. Culturing
ECs in conditioned medium from OPCs led to EC proliferation and angiogenesis by secreted factors,
such as transforming growth factor (TGF)-β and matrix metalloproteases (MMPs). OPCs support
BBB integrity by releasing either TGF-β1 in normal conditions, or disrupt it and induce angiogenesis
by releasing MMP-9 when stressed by inflammatory cytokines [80,81]. Taken together, these results
indicate that factors released by ECs and OPCs play an important role in promoting their interactions
and influencing their functions.
More recently, abnormal WNT signaling was suggested to alter the EC–OPC interaction, leading
to abnormal OPC migration and dysfunction of both ECs and OLs [82,83]. Hence, we performed a
systematic literature search to investigate the exact role of WNT signaling in the interaction between
ECs and OPCs/OLs and its involvement in cSVD.
7. Literature Search Method
Publications on ECs and OPCs/OLs and interaction related to cSVD were exclusively identified
through PubMed search engine and reported following the Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) [84]. The search was conducted on 9 April 2020 and
the following search terms and combinations were used to identify articles: Cerebral small vessel
disease AND endothelial cells; Cerebral small vessel disease AND endothelium; Cerebral small vessel
disease AND oligodendrocyte; Cerebral small vessel disease AND OPC; Cerebral small vessel disease
AND WNT; Oligodendrocyte AND endothelial; OPC AND endothelial; Endothelial AND interaction
AND (oligodendrocyte OR OPC OR OPC); Endothelial AND oligodendrocyte AND WNT; Endothelial
AND OPC AND WNT; WNT AND angiogenesis; WNT AND BBB AND oligodendrocyte; WNT AND
hypoperfusion; WNT AND hypertension; WNT7 AND endothelial; WNT7 AND oligodendrocyte.
Two additional relevant papers were later added by the authors.
Duplicate papers were removed, and studies underwent an initial screen based on their title,
followed by a screening of their abstract. Studies using the following terms were included during title
screening: Endothelial cells; oligodendrocytes and/or oligodendrocyte precursor cells; and cerebral
small vessel disease. Papers using the following terms were included after screening the abstract:
Interaction EC–OPC/OL; inflammation; vasculature; cerebrovascular; animal and human studies. We
excluded publications matching the following topics: Review, methodology, periphery, oncology, and
cancer. Furthermore, studies were excluded if they referred to EC interaction with OPCs or OLs in
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the context that was not related to the brain or irrelevant for cSVD (e.g., WNT signaling in brain
tumor environment) after full text reviewing. There were no commentaries, editorials, rectifications, or
non-English publications in our search results. Screening and extraction of articles was performed by
the first author (NM) under the guidance of the other authors. For each study, the following variables
were recorded: Language, year of publication, type of disease, clinical design, experimental design,
animal model, and results. The results are described in a flow diagram (Figure 2).
Figure 2. Flow diagram showing the systematic Preferred Reporting Items for Systematic review and
Meta-Analysis Protocols (PRISMA-P) search protocol and identification, screening, and extraction
of the corresponding studies. ECs, endothelial cells; OLs, oligodendrocytes; OPCs, oligodendrocyte
precursor cells; cSVD, cerebral small vessel disease.
8. WNT Signaling in Endothelial Cell–Oligodendrocyte Crosstalk
The key role of WNT/β-catenin signaling in various brain cells is subject to complex regulation.
Miyamoto et al. reviewed recent findings indicating a WNT-dependent single cell migration of
adult OPCs from the subventricular zone to damaged areas under the guidance of ECs, which may
contribute to white matter recovery [83]. Other findings supporting a key role for WNT signaling
in white matter recovery via OPC recruitment include the initial upregulation of WNT expression
in OPCs during hypoxia, WNT-mediated migration of OPCs, and an early increase of OPCs after
injury [50,52,85,86]. Evidence for a reciprocal interaction came from Iijima et al. by the induction
of remyelination due to EC dysfunction via endothelin (ET)-1 injection, indicated by a decrease in
immunohistochemical neuron-glial antigen 2 (NG2) and myelin basic protein (MBP) levels, which was
rescued by transplantation of healthy ECs. In addition, the results suggested a potential intrinsic rescue
mechanism via an increase in OPC density, 7 days after ET-1 injection [87]. EC dysfunction, indicated
by an impaired dilatation response to acetylcholine (ACh) and calcitonin gene-related peptide (CGRP),
and hypoperfusion, marked by an increased number of string vessels, due to TGF-β1 overexpression
in ECs in a transgenic mouse model led to a decreased OPC density in white matter areas and
cognitive impairment [77]. Treatment of EC dysfunction with simvastatin, a drug that improves
overall endothelial function [88], counteracted these negative effects, possibly via mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling [77]. This might indicate
a cross-talk with the WNT/β-catenin signaling pathway in the interaction of EC–OL, as MAPK can
increase β-catenin expression through direct phosphorylation of GSK3β by p38 [89]. These indirect
evidences suggest that EC dysfunction precedes OL dysfunction and white matter abnormalities,
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possibly via WNT signaling. We thus suggest that WNT/β-catenin signaling modulates both EC and
OL function and their interaction with potential pleiotropic roles in cSVD.
In cSVD animal models and patients, increased OPC proliferation and migration has been observed
following EC dysfunction [78,90]. Rajani et al. showed that SHRSP rats and human post-mortem
tissue displayed EC abnormalities before any classical signs of cSVD pathology or stroke. Direct
evidence for the ECs and OPCs/OLs interaction can be found in in vitro assays with OPCs cultured
with conditioned media from SHRSP rat primary brain microvascular EC cultures, which exhibit
decreased OPC differentiation and increased proliferation [78]. In vitro and in vivo increased OPC
density and proliferation together with an initial increase in OPCs, as observed in patients with
leukoencephalopathy, suggests an attempt by the brain to recruit myelinating cells for white matter
repair [78,87,90]. In fact, WNT signaling is involved in the migration of OPCs using the vascular
tree [72,85,86]. OPCs respond to demyelination by becoming activated, proliferating, migrating, and
ultimately differentiating into myelinating OLs [72]. Under physiological conditions, demyelination
results in the activation of WNT signaling in OPCs, which in turn leads to the upregulation of C-X-C
chemokine receptor type 4 (Cxcr4). This protein binds to its ligand stromal cell-derived factor 1 (Sdf1,
also known as C-X-C motif chemokine 12 [Cxcl12]) expressed by ECs and mediates the single cell
migration of OPCs to the recruitment site [85,86]. Tsai et al. showed that overexpressing Cxcr4 led
to increased attachment of OPCs to the vasculature and OPC clustering, which could be reversed by
inhibiting the Cxc4–Sdf1 interaction. Once these OPCs are at their intended destination, OPCs can
detach from the vessel and differentiate into mature myelinating OLs due to the downregulation of WNT
and Cxcr4. However, in disease states, abnormal EC function was shown to result in disruption of OPC
migration, OPC clustering, delayed OPC differentiation, and a decrease in myelination. These effects
might involve WNT signaling pathways as upregulation of Cxcr4 was detected in WNT-activated OPC
clusters [85]. OPC clusters were shown to be present in lesions in both animal models and human white
matter injury, where aberrant OPC migration and remyelination seem to be associated with overactive
WNT signaling [86]. These effects are both autocrine and paracrine, thus also affecting surrounding
ECs. OPCs are indeed able to activate WNT-mediated angiogenesis [52,72], and regulate it via the
expression of c-Cbl, acting as a negative feedback mechanism for WNT/β-catenin signaling [58]. These
results indicate an important role for OPC clustering in the dysregulation of EC and OPC function.
OPC clustering, and the dysfunctional overexpression of WNT signaling seen in Olig2-cre: APC
floxed/floxed mice, in turn lead to EC dysfunction, BBB disruption, and inflammation in non-injury
settings [86]. A key component in this process is the WNT-mediated expression of WNT inhibitory
factor 1 (Wif1), which is expressed following β-catenin activation. Wif1 is highly upregulated in OPCs,
activated due to WNT/β-catenin signaling, and functions as a negative feedback control mechanism
to decrease WNT activation in OPCs. However, overexpression of Wif1 also has a paracrine effect
on ECs by downregulating the TJ protein claudin5, leading to BBB dysfunction and subsequent
neuroinflammation [86]. Altogether, WNT/β-catenin signaling and its target genes are involved in the
tight regulation of the BBB and angiogenesis to adjust the blood supply according to demand. However,
this is a complex synergistic interaction since oxygen levels also influence WNT expression [52].
Hypoxic conditions lead to the upregulation of WNT7a and WNT7b, mediated by the stabilization
of hypoxia-inducible factor (HIF)1/2α, which resulted in decreased myelination in mouse white
matter [52,91]. These effects were normalized by XAV939, an inhibitor of WNT/β-catenin-mediated
transcription, via the stabilization of Axin [92]. Cell culture experiments also demonstrated an arrest of
OPC maturation when WNT signaling was overactive. In vitro, OPC-conditioned media promoted
β-catenin-mediated endothelial tip sprouting and tube formation in mouse brain ECs, which was
inhibited by XAV939 [52]. The secretion and release of WNT7a and WNT7b proteins from OPCs was
shown to directly induce angiogenesis and this was prevented by XAV939, demonstrating that this
effect was WNT/β-catenin dependent [52]. Wang et al. suggested that OPCs might have a positive
effect in reducing the infarct volume and brain edema and improving cognitive function after middle
cerebral artery occlusion in mice [82]. Transplantation of OPCs into the infarct area reduced protein
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leakage into the brain parenchyma, and rescued claudin5 expression. This was associated with an
upregulation of endothelial β-catenin and inhibition of WNT/β-catenin signaling, as using XAV939
increased BBB leakages and decreased claudin5 expression. These results are in agreement with in vitro
findings showing a decreased permeability of brain ECs treated with either WNT7a or OPC-conditioned
medium. In addition, WNT7a was upregulated in mice transplanted with OPCs, suggesting a key role
in this interaction. OPC-conditioned media or WNT7a treatment increased β-catenin and claudin5
expressions in brain ECs, an effect that was reversed by WNT7a knockdown in cultured OPCs [82].
Interestingly, recent evidence suggests that M2c anti-inflammatory microglia secrete WNT7a and
promote oligodendrogenesis, indicating that pleiotropic actions are also involved in microglia and OL
crosstalk [93].
9. Discussion
In summary, direct and indirect evidence suggests an interplay between ECs and OPCs/OLs
driven by WNT/β-catenin signaling. The mechanistic/molecular hypothesis of their interaction may
differ between physiological and pathological conditions as proposed below (Figure 3). We suggest
that the activation of WNT7a and WNT7b signaling in healthy ECs and OPCs/OLs in response to injury
may help the recruitment of new OPCs at sites of demyelination via the structural support of cerebral
vessels. In the meantime, this endothelial signaling promotes angiogenesis to supply oxygen and
necessary nutrients for recovery. Once OPCs have reached their destination, feedback mechanisms
are activated via Wif1, leading to the downregulation of WNT/β-catenin signaling. Subsequently,
angiogenesis stops and OPCs detach from the vessels to differentiate into mature myelinating OLs.
In cSVD however, local hypoxic injuries can alter the brain endothelium [52], causing activation of
HIF1/2α, which in turn excessively upregulates WNT7a and WNT7b signaling. Dysfunctional ECs
exhibit an overexpression of WNT proteins, leading to dysfunctional OPC migration and clustering,
and local angiogenesis. The expression of negative feedback proteins can have paracrine effects,
resulting in inflammation, abnormal angiogenesis, and a leaky BBB due to a low expression of the
TJ protein claudin5 in inflamed or newly formed vessels. EC dysfunction and WNT signaling may
also lead to decreased OPC detachment, leading to decreased OPC differentiation and decreased
myelination. Ultimately, these effects may stimulate further damage to the brain by decreasing the rate
of myelin repair, potentiating the development of WML and ensuing cognitive impairment.
Figure 3. Schematic overview of the proposed contribution of WNT/β-catenin signaling in cSVD. (A) In
a healthy situation, hypoxic injury induces WNT7a and WNT7b signaling in OPCs/OLs to promote the
recruitment of new OPCs at sites of demyelination. OPCs migrate to the site of injury partly by using
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the physical support offered by cerebral vessels. WNT/β-catenin signaling in ECs promotes angiogenesis
to supply oxygen and necessary nutrients for recovery. Once OPCs have reached their destination,
feedback mechanisms are activated via Wif1, leading to the downregulation of WNT/β-catenin signaling
and detachment from cerebral vessels. Subsequently, angiogenesis stops and OPCs differentiate into
mature OLs, capable of initiating remyelination. (B) In cSVD, activation of HIF1/2α due to local
hypoxia results in an exaggerated upregulation of WNT7a and WNT7b, which is aggravated by EC
dysfunction. This leads to dysfunctional OPC migration and clustering. Local angiogenesis induced
by WNT/β-catenin signaling results in a leaky and inflamed BBB partly due to the expression of
negative feedback proteins that alter the expression of the tight junction protein claudin5. In addition,
decreased detachment and differentiation of OPCs in turn leads to attenuated remyelination and white
matter repair.
10. Conclusions
It this review, we identified an important role for WNT signaling in the EC–OPC/OL interplay,
whose contribution (both autocrine and paracrine) should be further investigated. The use of animal
and post-mortem human material will be determinative to decipher the pleiotropic role of WNT in this
interaction and its relevance for cSVD pathobiology and other cerebrovascular disorders. Beyond a
greater pathological understanding, it may bring therapeutic opportunities to seal an impaired BBB,
reverse OPC clustering, and repair white matter injuries in cSVD.
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